Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paloma Cejas

Showing results (71-80 of 90) with videos related to

Pageof 9
Sort By:
Cancer Research|November 7, 2020
Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian CancerChangxin Wan, Matthew P Keany, Han Dong, et al.
Blood Cancer Discovery|January 11, 2022
BCOR and BCORL1 Mutations Drive Epigenetic Reprogramming and Oncogenic Signaling by Unlinking PRC1.1 from Target GenesEva J Schaefer, Helen C Wang, Hannah Q Karp, et al.
Cancer Discovery|February 16, 2021
Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint BlockadeShengqing Stan Gu, Wubing Zhang, Xiaoqing Wang, et al.
Nature Medicine|September 11, 2019
Publisher Correction: Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumorsPaloma Cejas, Yotam Drier, Koen M A Dreijerink, et al.
Science Advances|November 24, 2021
Predicting master transcription factors from pan-cancer expression dataJessica Reddy, Marcos A S Fonseca, Rosario I Corona, et al.
Nature Medicine|July 3, 2019
Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumorsPaloma Cejas, Yotam Drier, Koen M A Dreijerink, et al.
Nature Communications|May 13, 2022
MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targetsXintao Qiu, Nadia Boufaied, Tarek Hallal, et al.
Nature Cancer|May 17, 2021
CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activityApril C Watt, Paloma Cejas, Molly J DeCristo, et al.
JCI Insight|January 23, 2026
EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapyAtsuko Ogino, Amir Vajdi, Xinmeng Jasmine Mu, et al.
Cancer Cell|May 8, 2026
Whole-genome doubling drives immune evasion by silencing antigen presentationPierre Foidart, Zheqi Li, Xinran Cai, et al.
Pageof 9

Showing results (71-80 of 90) with videos related to

Sort By:
Pageof 9
Cancer Research|November 7, 2020
Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian CancerChangxin Wan, Matthew P Keany, Han Dong, et al.
Blood Cancer Discovery|January 11, 2022
BCOR and BCORL1 Mutations Drive Epigenetic Reprogramming and Oncogenic Signaling by Unlinking PRC1.1 from Target GenesEva J Schaefer, Helen C Wang, Hannah Q Karp, et al.
Cancer Discovery|February 16, 2021
Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint BlockadeShengqing Stan Gu, Wubing Zhang, Xiaoqing Wang, et al.
Nature Medicine|September 11, 2019
Publisher Correction: Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumorsPaloma Cejas, Yotam Drier, Koen M A Dreijerink, et al.
Science Advances|November 24, 2021
Predicting master transcription factors from pan-cancer expression dataJessica Reddy, Marcos A S Fonseca, Rosario I Corona, et al.
Nature Medicine|July 3, 2019
Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumorsPaloma Cejas, Yotam Drier, Koen M A Dreijerink, et al.
Nature Communications|May 13, 2022
MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targetsXintao Qiu, Nadia Boufaied, Tarek Hallal, et al.
Nature Cancer|May 17, 2021
CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activityApril C Watt, Paloma Cejas, Molly J DeCristo, et al.
JCI Insight|January 23, 2026
EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapyAtsuko Ogino, Amir Vajdi, Xinmeng Jasmine Mu, et al.
Cancer Cell|May 8, 2026
Whole-genome doubling drives immune evasion by silencing antigen presentationPierre Foidart, Zheqi Li, Xinran Cai, et al.
Pageof 9